Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/16/2017 08/17/2017 08/18/2017 08/21/2017 08/22/2017 Date
468.54(c) 464.02(c) 467.98(c) 469.74(c) 478.65(c) Last
383 329 711 648 549 722 510 675 503 575 Volume
-0.85% -0.96% +0.85% +0.38% +1.90% Change
More quotes
Financials ($)
Sales 2017 5 746 M
EBIT 2017 2 358 M
Net income 2017 1 328 M
Finance 2017 2 375 M
Yield 2017 -
Sales 2018 6 241 M
EBIT 2018 2 656 M
Net income 2018 1 449 M
Finance 2018 3 093 M
Yield 2018 -
P/E ratio 2017 41,76
P/E ratio 2018 38,36
EV / Sales2017 8,51x
EV / Sales2018 7,72x
Capitalization 51 288 M
More Financials
Company
Regeneron Pharmaceuticals, Inc. operates as a biopharmaceutical company.It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.The company involves in marketing medicines for eye diseases, colorectal cancer and a rare inflammatory... 
More about the company
Surperformance© ratings of Regeneron Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on REGENERON PHARMACEUTICALS
08/18 REGENERON PHARMACEUTICALS : `s (REGN) RSV Drug Suptavumab Fails NURSERY Trial
08/15 TWO FAILED TRIALS : Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) and Regeneron Ph..
08/14DJHot Stocks to Watch in the U.S. and Canada
08/14 REGENERON PHARMACEUTICALS : to Discontinue Development of Suptavumab for Respira..
08/11 REGENERON PHARMACEUTICALS : Baltimore Native Awarded Regeneron Prize for Medical..
08/10 REGENERON PHARMACEUTICALS : Accessing the Regeneron Second Quarter 2017 Financia..
08/10 REGENERON PHARMACEUTICALS : Researchers Submit Patent Application, "Fucosylation..
08/03 REGENERON PHARMACEUTICALS : "Use of a Vegf Antagonist to Treat Angiogenic Eye Di..
08/03 REGENERON PHARMACEUTICALS : Accessing the Regeneron Second Quarter 2017 Financia..
08/03 REGENERON PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CO..
More news
Sector news : Bio Therapeutic Drugs
08/17 FDA expands use of AstraZeneca/Merck ovarian cancer drug
08/15 Three CEOs resign from Trump council over Charlottesville
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
More sector news : Bio Therapeutic Drugs
4-Traders Strategies on REGENERON PHARMACEUTICALS 
08/21One can take advantage of the trading range to enter new positions
More Strategies
Latest Tweets
05:03aRegeneron Pharmaceuticals, Inc. $REGN Receives Average Recommendation of “Hol.. 
08/22Prices for those expensive cholesterol drugs would have to drop a lot to be c.. 
08/22$REGN day highs with weekly $485 calls seeing 165 bought, moving out of a nic..
3
08/21Ophthotech: 3 Strikes And It's Out?  
08/21State Board of Administration of Florida Retirement System Has $56.64 Million.. 
More tweets
Qtime:72
News from SeekingAlpha
08/21 Seeking Confirmations - U.S. Stock Market
08/21 OPHTHOTECH : 3 Strikes And It's Out?
08/17 Evercore ISI initiates 14 bullish calls, 9 neutral
08/15 3 THINGS IN BIOTECH YOU SHOULD LEARN : August 15, 2017
08/14 Regeneron's suptavumab fails to beat placebo in preventing RSV infection in i..
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 494 $
Spread / Average Target 3,3%
EPS Revisions
Managers
NameTitle
Leonard S. Schleifer President, Chief Executive Officer & Director
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
George Damis Yancopoulos Director & Chief Scientific Officer
Neil Stahl Executive VP-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS27.48%51 288
AMGEN14.42%122 702
CELGENE CORPORATION10.09%99 695
GILEAD SCIENCES0.70%94 810
VERTEX PHARMACEUTICALS102.27%37 568
ACTELION22.00%30 289